Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY

Does first-line surgery still have its place in the treatment of acromegaly?

(2009) F. Castinetti et al.   ANNALES D ENDOCRINOLOGIE

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients

(2009) SJCMM Neggers et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy

(2009) Mónica Marazuela et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

ACROSTUDY: the first 5 years

(2009) Peter J Trainer   EUROPEAN JOURNAL OF ENDOCRINOLOGY

ACROSTUDY: Status Update on 469 Patients

(2009) Thierry Brue   Hormone Research in Paediatrics

Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials

(2008) Camilo Jimenez et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant

(2008) S. J. C. M. M. Neggers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Radiotherapy and radiosurgery in acromegaly

(2008) Frédéric Castinetti et al.   Pituitary

Acromégalie

(2008) Philippe Chanson   PRESSE MEDICALE